UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000178
Receipt number R000000248
Scientific Title Phase II Clinical Trial to Test Efficacy and Safety of Autologous Peripheral Stem Cell Transplantation for Multiple Myeloma (C-SHOT 0401)
Date of disclosure of the study information 2005/09/12
Last modified on 2016/11/02 10:45:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II Clinical Trial to Test Efficacy and Safety of Autologous Peripheral Stem Cell Transplantation for Multiple Myeloma (C-SHOT 0401)

Acronym

Clinical Trial to Test Efficacy and Safety of Autologous Peripheral Stem Cell Transplantation for Multiple Myeloma (C-SHOT 0401)

Scientific Title

Phase II Clinical Trial to Test Efficacy and Safety of Autologous Peripheral Stem Cell Transplantation for Multiple Myeloma (C-SHOT 0401)

Scientific Title:Acronym

Clinical Trial to Test Efficacy and Safety of Autologous Peripheral Stem Cell Transplantation for Multiple Myeloma (C-SHOT 0401)

Region

Japan


Condition

Condition

multiple myeloma

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To test efficacy and safety of a series of treatment from induction chemotherapy to single peripheral autologous transplantation for patients with newly diagnosed multiple myeloma.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Response rate after 90 days from the transplantation

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Therapy is composed of the following three steps of therapy.
1. induction chemotherapy(3 courses of C-VAD regimen)
2. peripheral stem cell collection after high dose cyclophosphamide
3. autologous peripheral stem cell transplantation after high dose melphalan

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Multiple Myeloma(SWOG criteria).
2. Durie&Salomon Stage II or III.
3. No previous treatments
4. age >=16 and <= 65
5. PS 0-2(ECOG)
6. No clinically significant abnormalities in liver, heart and pulmonary functions
7. Written informed consent

Key exclusion criteria

1. Severe renal dysfunction
2. Severe cardiovascular dysfunction
3. Active infections
4. Active opportunistic infections
5. Active double cancers
6. Subjects who, in the opinion of the investigator, are not likely to participate in the study for any reason

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Isamu Sugiura

Organization

Toyohashi Municipal Hospital

Division name

Division of Hematology

Zip code


Address

50 Hakken-Nishi, Aotake-cho, Toyohashi #441-8570

TEL

0532-33-6111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Isamu Sugiura

Organization

Toyohashi Municipal Hospital

Division name

Division of Hematology

Zip code


Address

50 Hakken-Nishi, Aotake-cho, Toyohashi #441-8570

TEL

0532-33-6111

Homepage URL

http://www.c-shot.or.jp/

Email

isugiura-sgr@umin.ac.jp


Sponsor or person

Institute

Center for Supporting Hematology-Oncology Trials (C-SHOT)

Institute

Department

Personal name



Funding Source

Organization

Nagoya BMT group

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

JAPAN


Other related organizations

Co-sponsor

Nagoya Muliple Myeloma Collaborated Group

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2005 Year 09 Month 12 Day


Related information

URL releasing protocol

http://www.c-shot.or.jp/

Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2004 Year 03 Month 26 Day

Date of IRB


Anticipated trial start date

2004 Year 04 Month 01 Day

Last follow-up date

2012 Year 07 Month 01 Day

Date of closure to data entry

2013 Year 03 Month 01 Day

Date trial data considered complete

2013 Year 05 Month 01 Day

Date analysis concluded

2013 Year 12 Month 01 Day


Other

Other related information



Management information

Registered date

2005 Year 09 Month 12 Day

Last modified on

2016 Year 11 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000248


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name